Atlas Capital Advisors Inc. Purchases 3,960 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Atlas Capital Advisors Inc. increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2,385.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,126 shares of the medical equipment provider's stock after buying an additional 3,960 shares during the quarter. Atlas Capital Advisors Inc.'s holdings in Zimmer Biomet were worth $436,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter worth about $25,000. Dunhill Financial LLC lifted its holdings in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after buying an additional 218 shares during the period. Kentucky Trust Co bought a new stake in Zimmer Biomet during the 4th quarter valued at approximately $39,000. OFI Invest Asset Management purchased a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $40,000. Finally, SRS Capital Advisors Inc. raised its position in shares of Zimmer Biomet by 146.9% in the 4th quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider's stock worth $51,000 after acquiring an additional 285 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH traded down $1.81 on Thursday, reaching $101.63. The company's stock had a trading volume of 1,045,334 shares, compared to its average volume of 1,613,385. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $128.55. The stock has a market capitalization of $20.23 billion, a P/E ratio of 22.87, a PEG ratio of 1.95 and a beta of 0.84. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock's 50 day simple moving average is $106.54 and its two-hundred day simple moving average is $107.10.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.95% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ZBH shares. JMP Securities reaffirmed a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Truist Financial reiterated a "hold" rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, Royal Bank of Canada lowered their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.